Morningside

Founded in 2013 and based in Cambridge, Massachusetts, CollegeVine is a technology company that specializes in developing artificial intelligence platforms to replace administrative tasks within the higher education sector. Its primary goal is to save time and money for universities globally by deploying safe AI agents, aiming to make higher education sustainable and efficient.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Almond Fintech, headquartered in Boston and Singapore, is a blockchain-based infrastructure facilitating cross-border funds transfers for financial institutions worldwide. The company connects hundreds of institutions, allowing millions of users to send money internationally through their existing financial services. Almond's platform is designed for speed, security, and accessibility, and includes a suite of APIs that support peer-to-peer transfers and digital currency-based settlements. Additionally, it offers interoperability between various mobile wallets and services, enabling both individuals and businesses to efficiently conduct remittances and payments across different providers and borders.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

DeepCure Inc. is a biotechnology company based in Boston, Massachusetts, specializing in artificial intelligence-driven drug discovery. Founded in 2018, DeepCure develops innovative solutions for small-molecule drug development, utilizing advanced deep learning algorithms and a proprietary database of chemical compounds. The company offers services such as De-novo Lead Discovery, which employs AI algorithms to assess potential drug candidates from a virtual library, and Artificial Intelligence-driven Lead Optimization, aimed at enhancing drug development processes. Additionally, DeepCure's platform includes a molecular database designed to maximize the diversity and synthesizability of chemical compounds. By integrating AI predictive modeling and a feedback loop, DeepCure focuses on creating effective therapeutics for unmet medical needs, ultimately aiming to expedite the development of novel precision medicines.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, employing sensors, music, and artificial intelligence to create evidence-based interventions aimed at enhancing walking and overall functional outcomes. Founded in 2015 and headquartered in Portland, Maine, the company addresses the needs of individuals affected by neurological conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. By merging music with neuroscience and technology, MedRhythms develops programs that focus on sensorimotor, speech, language, and cognitive rehabilitation goals, allowing patients to leverage music as a therapeutic tool to stimulate brain function and improve their quality of life.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Founded in 2018, Fount Bio is a life science company based in Cambridge, Massachusetts. It specializes in developing biopolymer-based products to enhance tissue rejuvenation, utilizing proprietary bioorthogonal chemistry for targeted delivery of glycopolymers. This approach aims to improve product performance and patient outcomes in aesthetics and medical dermatology.

Linus Health, Inc. is a digital health company based in Waltham, Massachusetts, founded in 2019. It specializes in developing a brain health monitoring platform that utilizes digital screening technology to enhance the assessment and treatment of cognitive and mental health. The platform collects various digital measurements, including voice, speech, gait, cognition, and eye movement, aimed at early detection and diagnosis of brain health issues. Additionally, Linus Health provides clinical decision support and care planning tools, enabling healthcare providers to offer actionable recommendations based on the insights gathered. The company's mission focuses on transforming brain health, making it accessible to individuals worldwide.

Founded in 2017, Coin Metrics provides comprehensive crypto financial intelligence. It offers network data, market data, indexes, and risk management solutions to institutions, empowering them with transparent and actionable insights for informed decision-making.

Catalant is a Boston-based software company that specializes in strategy execution solutions for global enterprises. Founded in 2013, the company's platform enables businesses to break down strategic objectives, access and deploy resources, collaborate, measure value, and improve processes. Catalant's network comprises over 65,000 experts and 1,000 firms, serving more than 30% of the Fortune 100. Additionally, Catalant offers a platform that connects private equity firms with business professionals.

Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, Apnimed aims to address the underlying neurobiological mechanisms that contribute to obstructive sleep apnea (OSA), a serious condition affecting over 20 million Americans. Current treatment options primarily involve positive pressure devices, which can be cumbersome, while Apnimed's approach seeks to provide a simpler, safe, and effective orally dosed medication. The company's therapeutics target both the physiological and symptomatic effects of OSA, with the goal of improving daily functioning and reducing the significant morbidity and mortality associated with this disorder.

Stavvy is a financial technology company that develops digital platforms for mortgage banking professionals. Its core products are Stavvy Connect, which facilitates secure communication and data sharing between lenders and vendors during home loan processes, and Stavvy Notarize, enabling real-time virtual closings and meetings via web conference technology.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing next-generation antiviral therapeutics for severe viral diseases. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by the SARS-CoV-2 virus. Additionally, Atea is advancing several candidates in clinical trials, including AT-787 for hepatitis C and AT-752 for dengue, both in phase 2 trials. The company aims to provide innovative treatments for infections caused by RNA and DNA viruses, improving outcomes for patients suffering from serious viral infections. Atea Pharmaceuticals was incorporated in 2012.

Prospective Research, Inc., based in Beverly, Massachusetts, specializes in developing innovative solutions for antibiotic discovery and disease management in aquaculture. Founded in 2015, the company utilizes its proprietary MicrobeMiner platform to access untapped antibiotics by mimicking natural soil stimuli. Its GeneMiner technology aligns specific microbes with targeted stimuli, while the StimKeys technology reproduces these stimuli to unlock microbial natural products. Additionally, Prospective Research is pioneering feed-integrated preventative disease management solutions that eliminate the need for traditional antibiotics in aquaculture. By employing microbial signaling molecules, the company can modulate bacterial behavior and deliver therapeutics directly to the gut of farmed species. Prospective Research introduces trillions of beneficial bacteria into the microbiome of fin-fish, shrimp, and shellfish, enabling selective activation of bacterial genes that produce bio-active therapeutics to combat various pathogens.

Breezeway is a software company that offers an intelligent property care and maintenance platform. The Breezeway platform helps property managers coordinate, communicate, and verify tasks and service experiences across vacation rentals, residential rentals, corporate housing, hotels, and cleaning services. It combines inspections, cleanliness readiness monitoring, and task management with automated workflows, smart messaging, and mobile-first tools to improve quality, efficiency, and turnover. The platform leverages robust property data and deep learning technology to support scheduling, asset management, safety and compliance, owner relations, and guest communications, while coordinating work with internal staff or remote service partners. Founded in 2015 and based in Boston, Breezeway aims to streamline property operations and enhance the overall service experience for tenants and guests.

Pinteon Therapeutics, Inc. is a biotechnology company founded in 2014 and based in Newton, Massachusetts. The company specializes in developing innovative therapeutics aimed at slowing down neurodegeneration and preserving brain function by interrupting the spread of toxic tau proteins. Pinteon focuses on the discovery and development of therapeutics that target the Pin1 protein, which plays a crucial role in regulating various disease processes, including those associated with cancer, central nervous system disorders, and autoimmune diseases. By inhibiting or activating Pin1, Pinteon Therapeutics aims to normalize these aberrant disease processes, ultimately improving patient outcomes in areas of significant unmet medical need.

Founded in 2013 and based in Cambridge, Massachusetts, CollegeVine is a technology company that specializes in developing artificial intelligence platforms to replace administrative tasks within the higher education sector. Its primary goal is to save time and money for universities globally by deploying safe AI agents, aiming to make higher education sustainable and efficient.

Apic Bio develops gene therapies targeting rare neurological and liver diseases. Its lead product, APB-101, uses an adeno-associated virus vector to silence and augment proteins for treating alpha-1 antitrypsin deficiency.

Peach is a Seattle-based company founded in 2014 that partners with local restaurants to provide curated lunch services for businesses in major metropolitan areas, including Seattle, Boston, and Phoenix. The company aims to enhance employee productivity by delivering wholesome and fulfilling lunch options directly to workplaces. Through its mobile application, Peach offers a convenient platform for companies to access daily menus from partnered restaurants and place orders either individually or in groups. This service not only streamlines the lunch experience for employees but also enables businesses to implement subsidized meal programs, promoting a supportive work environment. In recognition of its innovative approach, Peach was awarded the Geekwire Top 200 Pacific Northwest Start-Ups in 2015.

Founded in 2015, Ground Signal is a Boston-based company specializing in location-based audience analytics. Its platform enables brands to understand and reach real-world consumers and influencers by analyzing over 5 million offline behaviors daily, providing insights into customer profiles, behaviors, and locations.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Founded in 2013 and based in Cambridge, Massachusetts, CollegeVine is a technology company that specializes in developing artificial intelligence platforms to replace administrative tasks within the higher education sector. Its primary goal is to save time and money for universities globally by deploying safe AI agents, aiming to make higher education sustainable and efficient.

Freight Farms manufactures crop production units housed in upcycled shipping containers, notably the Leafy Green Machine, a hydroponic farming system capable of delivering commercial-scale yields in any climate or season. The platform is an assembled hydroponic setup inside a container and supports growing a range of crops, including lettuces, herbs such as mint and basil, and brassica greens. It serves business owners, schools, municipalities, and other organizations across the United States, Canada, and Europe, enabling on-site, year-round production to support local food economies and sustainable supply chains. The company is based in Boston, Massachusetts.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

LovePop Inc., established in 2014 and based in Boston, Massachusetts, specializes in designing and manufacturing unique, laser-cut pop-up greeting cards. The company offers a wide range of cards for various occasions such as birthdays, holidays, and Valentine's Day, selling them through outlets in Boston, Northern California, Southern California, Las Vegas, and online. LovePop aims to strengthen personal relationships by providing innovative, interactive greeting card options that go beyond traditional digital connections.

Founded in 2013 and based in Cambridge, Massachusetts, CollegeVine is a technology company that specializes in developing artificial intelligence platforms to replace administrative tasks within the higher education sector. Its primary goal is to save time and money for universities globally by deploying safe AI agents, aiming to make higher education sustainable and efficient.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Vigeo Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutic agents for the treatment of advanced malignant tumors. Established in 2011, the company specializes in a first-in-class drug discovery pipeline that aims to reprogram the tumor immune microenvironment to enhance cancer treatment outcomes. One of its key products is a peptide fragment derived from the prosaposin protein, which inhibits metastasis and tumor growth by stimulating the production of an inhibitory molecule within the tumor microenvironment. Vigeo Therapeutics plans to initiate multiple combination studies to evaluate its lead candidate, VT1021, alongside chemotherapies and anti-PD-1 antibodies, with the goal of improving treatment options for various cancer types and enhancing patient quality of life.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Synchroneuron Inc. is a biopharmaceutical company focused on developing innovative therapies for tardive dyskinesia and other neuropsychiatric disorders. Founded in 2011 and based in Duxbury, Massachusetts, the company is advancing its lead candidate, SNC-102, a sustained-release formulation of acamprosate calcium. This novel drug aims to enhance pharmacokinetic properties compared to existing formulations and is currently undergoing phase 2 clinical trials for tardive dyskinesia and Tourette syndrome, as well as phase 1 trials for combat-related posttraumatic stress disorder. By targeting the modulation of excitatory and inhibitory neurotransmission within subcortical neural loops, Synchroneuron seeks to address the involuntary movements characteristic of these conditions.

Freight Farms manufactures crop production units housed in upcycled shipping containers, notably the Leafy Green Machine, a hydroponic farming system capable of delivering commercial-scale yields in any climate or season. The platform is an assembled hydroponic setup inside a container and supports growing a range of crops, including lettuces, herbs such as mint and basil, and brassica greens. It serves business owners, schools, municipalities, and other organizations across the United States, Canada, and Europe, enabling on-site, year-round production to support local food economies and sustainable supply chains. The company is based in Boston, Massachusetts.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Synchroneuron Inc. is a biopharmaceutical company focused on developing innovative therapies for tardive dyskinesia and other neuropsychiatric disorders. Founded in 2011 and based in Duxbury, Massachusetts, the company is advancing its lead candidate, SNC-102, a sustained-release formulation of acamprosate calcium. This novel drug aims to enhance pharmacokinetic properties compared to existing formulations and is currently undergoing phase 2 clinical trials for tardive dyskinesia and Tourette syndrome, as well as phase 1 trials for combat-related posttraumatic stress disorder. By targeting the modulation of excitatory and inhibitory neurotransmission within subcortical neural loops, Synchroneuron seeks to address the involuntary movements characteristic of these conditions.

Founded in 2006, Oxyrane UK Limited is a biopharmaceutical company based in Manchester, United Kingdom. It develops novel enzyme replacement therapies using its proprietary glycoengineering platform to treat lysosomal storage diseases.

Founded in 2008, Clean Membranes specializes in producing innovative, anti-fouling membranes for diverse water treatment applications. Its proprietary smart copolymer membranes enhance water flow and fouling resistance, improving filter performance and longevity across municipal, industrial, pharmaceutical, food industry, oil and gas extraction, and seawater desalination sectors.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

ThingMagic, Inc. is a prominent developer of UHF radio frequency identification (RFID) technology, specializing in the design, manufacture, and sale of RFID engines, readers, and development platforms for various applications. Founded in 2000 and headquartered in Woburn, Massachusetts, the company offers a diverse range of products, including fixed and embedded RFID readers, antennas, and the ThingMagic Mercury xPRESS Platform, which allows for the development of application-specific RFID solutions. ThingMagic serves a wide array of customers, including major retailers, automotive firms, manufacturers, and companies in industrial automation, providing both products and professional services to facilitate the integration of RFID technology into consumer and industrial products. As of January 2017, ThingMagic operates as a subsidiary of Novanta Corporation.

Serica Technologies, Inc. is a medical device company based in Medford, Massachusetts, specializing in silk-based biomaterial platforms for tissue repair. The company develops innovative products, including SeriGel, a bioresorbable silk hydrogel for plastic and reconstructive surgery and drug delivery, and SeriFascia, a surgical scaffold implant that aids in restoring collagen tissue affected by surgery or aging. Additionally, Serica offers SeriACL, a biodegradable ligament graft for anterior cruciate ligament repair, SeriCuff for rotator cuff tendon repair, and SeriScaffold surgical mesh for repairing damaged connective tissues. The company's products serve various applications in orthopedics, sports medicine, and aesthetic and reconstructive surgery. Founded in 1998, Serica Technologies was previously known as Tissue Regeneration, Inc. and rebranded in 2006.

ThingMagic, Inc. is a prominent developer of UHF radio frequency identification (RFID) technology, specializing in the design, manufacture, and sale of RFID engines, readers, and development platforms for various applications. Founded in 2000 and headquartered in Woburn, Massachusetts, the company offers a diverse range of products, including fixed and embedded RFID readers, antennas, and the ThingMagic Mercury xPRESS Platform, which allows for the development of application-specific RFID solutions. ThingMagic serves a wide array of customers, including major retailers, automotive firms, manufacturers, and companies in industrial automation, providing both products and professional services to facilitate the integration of RFID technology into consumer and industrial products. As of January 2017, ThingMagic operates as a subsidiary of Novanta Corporation.

ThingMagic, Inc. is a prominent developer of UHF radio frequency identification (RFID) technology, specializing in the design, manufacture, and sale of RFID engines, readers, and development platforms for various applications. Founded in 2000 and headquartered in Woburn, Massachusetts, the company offers a diverse range of products, including fixed and embedded RFID readers, antennas, and the ThingMagic Mercury xPRESS Platform, which allows for the development of application-specific RFID solutions. ThingMagic serves a wide array of customers, including major retailers, automotive firms, manufacturers, and companies in industrial automation, providing both products and professional services to facilitate the integration of RFID technology into consumer and industrial products. As of January 2017, ThingMagic operates as a subsidiary of Novanta Corporation.